Category Archives: EQS Newsfeed

DoctorBox Adds Mainz Biomed’s ColoAlert® to Its Portfolio

Posted on by

Issuer: Mainz BioMed N.V.

/ Key word(s): Miscellaneous

DoctorBox Adds Mainz Biomed’s ColoAlert® to Its Portfolio

02.12.2025 / 14:01 CET/CEST

The issuer is solely responsible for the content of this announcement.

DoctorBox Adds Mainz Biomed’s ColoAlert® to Its Portfolio 

DNA-based Colorectal Cancer Screening as a Home Test 

BERKELEY, US, MAINZ and BERLIN, Germany – December 02, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company“), molecular genetics diagnostic company specializing in the early detection of cancer,today announced that its test ColoAlert® has been added to the portfolio of DoctorBox, one of Germany’s leading pioneers in digital health. This marks another important milestone in Mainz Biomed’s European growth strategy and highlights the increasing importance of innovative, personalized solutions in preventive medicine. Laboratory analysis will be performed by Mainz Biomed’s long-standing partner, the European Oncology Lab, led by Dr. med. Annette Buhlmann in St. Ingbert, Germany.

Colorectal cancer is one of the most common yet preventable cancers worldwide. In Germany alone, around 60,000 new cases are diagnosed each year — a clear indicator of the need for highly effective early detection measures. By integrating Mainz Biomed’s advanced DNA diagnostics into DoctorBox’s digital healthcare platform, this collaboration establishes a highly innovative model of care that can significantly expand access to ColoAlert.

“With DoctorBox, we are gaining a strong partner that enables us to offer ColoAlert exactly where prevention can take place today — at home,” said Guido Baechler, CEO of Mainz Biomed. “Together, we are lowering barriers to colorectal cancer screening and providing easy access to DNA-based early detection.”

“ColoAlert fits perfectly into our portfolio of next-generation DNA- and RNA-based tests. Thus, innovative colorectal cancer screening becomes another cornerstone of our digital preventive healthcare platform,” said Julian Maar, CEO of DoctorBox.

The DoctorBox app brings together modern preventive healthcare services on a single platform: with over one million registered users and more than ten million test results transmitted, DoctorBox ranks among Europe’s leading digital prevention solutions. The offering includes guideline-based preventive-care reminders – personalized by age, sex, and risk profile. Additional services include at-home tests and locally accessible diagnostics, for example for early detection of colorectal, cervical, and prostate cancer (self-pay or reimbursed). Measures for sexual health, allergies, as well as innovative analyses, digital evaluation and support – including the delivery of findings, recommendations for action, and video consultations directly within the app – are also part of the DoctorBox offering.

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About DoctorBox

DoctorBox is setting the new standard for prevention in Europe — made in Germany.

As one of Germany’s leading digital solutions for smart preventive healthcare, DoctorBox empowers more than one million users in Germany and other European countries to manage their health prevention easily, digitally, and independently. Whether through reminders, at-home tests, or local diagnostics, DoctorBox makes preventive healthcare accessible and part of everyday life.

To learn more, visit doctorbox.de.

About Mainz Biomed NV

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples.

To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.

For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu

For investor inquiries, please contact ir@mainzbiomed.com

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025 and its mid-year report on Form 6-K filed on September 26, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Language: English
Company: Mainz BioMed N.V.
Robert-Koch-Strasse 50
55129 Mainz
Germany
Internet: mainzbiomed.com
EQS News ID: 2236234

 
End of News EQS News Service

Xlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity

Posted on by

NeuroMex delivers 83.5% accuracy in identifying early-stage Alzheimer’s without traditional cognitive tests, enabling rapid, scalable preventive screening. With the device now entering the partnering phase, it is poised to become a standard component of annual health examinations, opening significant revenue streams and strategic partnership opportunities in healthcare and pharmaceuticals.

«NeuroMex transforms early detection, allowing timely interventions and optimized resource use in healthcare,» said Jenny Nisser, Managing Director of saniva diagnostics GmbH. Oliver R. Baumann, CEO of Xlife Sciences AG added that «this positions Xlife Sciences at the forefront of a multi-billion-dollar market for neurodegenerative diagnostics and preventative care.»

By combining breakthrough science, regulatory approval, and clinical validation, Xlife Sciences is uniquely positioned to drive adoption, accelerate partnerships, and deliver meaningful impact for patients, healthcare systems, and investors.

 

Financial calendar

Annual Report 2025 28 April 2026
Annual Shareholders Meeting 2026 26 June 2026
Half-Year Report 2026 24 September 2026

Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients

Posted on by
  • Wyost® (denosumab 120 mg) / Jubbonti® (denosumab 60 mg) approved to treat cancer-related bone disease / osteoporosis across all indications of reference medicines
  • Next milestone in Sandoz growth strategy; builds on 2025 launches of Wyost® (denosumab) / Jubbonti® (denosumab) and Tyruko® (natalizumab) in US and Afqlir® (aflibercept) in Europe
  • Builds on established position in oncology and immunology
  • Reinforces Sandoz commitment to helping patients access critical and potentially life-changing biologic medicines through leading global portfolio and pipeline 

Basel, December 1, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, today announced the European launch of Wyost® (denosumab 120 mg) and Jubbonti® (denosumab 60 mg). The medicines are among the first denosumab biosimilars to launch in Europe and are approved by the European Commission to treat all indications of the reference medicines, Xgeva®* (denosumab 120 mg) and Prolia®* (denosumab 60 mg)1,2. Wyost® is approved for the treatment of cancer-related bone disease1 and Jubbonti® is approved to treat osteoporosis2.

 

Wyost® and Jubbonti® represent key value drivers for Sandoz and the European launch marks the next major step in advancing the company’s growth strategy. It builds on other key biosimilar launches this year including Wyost® and Jubbonti® in the US and the recent launches of Tyruko® (natalizumab) in the US and Afqlir® (aflibercept) in Europe.

 

Christophe Delenta, President Europe, Sandoz, said: “We know that primary and secondary bone loss, and cancer-related bone events, place a significant burden on millions of patients and their families, as well as on European healthcare systems. That’s why the launch of these denosumab biosimilars is such an important milestone, expanding access to these potentially life-changing medicines and reinforcing our commitment to delivering sustainable treatment options for patients.”

 

Close to one quarter (4.14 million)3 of all newly reported cancer cases globally occur in Europe and cancer remains a leading cause of premature death for people aged 30-69 years in most European countries4. Nearly all types of cancer can spread to the bone and cause pain and fractures, but cancers that often metastasize there include breast, lung and prostate5.

 

According to the latest figures, 32 million people in Europe over 50 years old are estimated to live with osteoporosis, with the number of fractures per year set to increase by almost 25% by 20346. Only a minority of patients at high risk currently receive treatment, even after their first fracture7.

 

Wyost® and Jubbonti® will be launched across Europe today, with additional rollouts to follow throughout 2026. This launch builds on the continuing Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. It further expands the company’s presence in a global reference-medicine market worth a combined ~USD 6.6 billion8 and reinforces its established position in oncology and immunology.  

 

Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably, with a leading global portfolio comprising 13 biosimilars and a further 27 assets in various stages of development.

 

*Xgeva® and Prolia® are registered trademarks of Amgen Inc.

 

ABOUT WYOST® (DENONSUMAB) AND JUBBONTI® (DENOSUMAB)

Wyost® (denosumab 120 mg) and Jubbonti® (denosumab 60 mg) have been developed as biosimilars to the reference medicines Xgeva and Prolia, respectively1,2. Both medicines contain the same active ingredient (denosumab), a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing activation of its receptor, RANK, on the surface of osteoclast precursors and osteoclasts. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone.

 

Wyost® is indicated in Europe to prevent skeletal related events (SREs; pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone, and to treat adults and skeletally mature adolescents with a giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity1.

 

Jubbonti® is indicated in Europe to treat osteoporosis in postmenopausal women and in men at increased risk of fractures, bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures and bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture2.

 

DISCLAIMER

This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.

 

REFERENCES

1 European Medicines Agency (EMA). Wyost (denosumab): Prescribing Information.
Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/wyost [Last accessed: November 2025].

2 European Medicines Agency (EMA). Jubbonti (denosumab): Prescribing Information. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/jubbonti [Last accessed: November 2025].

3 Elmadani, M., Mokaya, P.O., Omer, A.A.A. et al. Cancer burden in Europe: a systematic analysis of the GLOBOCAN database (2022). BMC Cancer 25, 447 (2025). Available from: https://doi.org/10.1186/s12885-025-13862-1 [Last accessed: November 2025].

4 The Cancer Atlas. The Burden of Cancer. Available from: https://canceratlas.cancer.org/burden-of-cancer/ [Last accessed: November 2025].

5 American Cancer Society. Bone Metastases. Available from: https://www.cancer.org/treatment/understanding-your-diagnosis/advanced-cancer/bone-metastases.html [Last accessed: November 2025].

6 International Osteoporosis Foundation. SCOPE ’21. ScoreCard for OsteoPorosis in Europe. Available from: https://www.osteoporosis.foundation/sites/iofbonehealth/files/2022-01/Slide%20set%20-%20EU%20general.pdf [Last accessed: November 2025].

7 International Osteoporosis Foundation. Facts and Statistics. Available from: https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures [Last accessed: November 2025].

8 Amgen. Letter to Shareholders and Annual Report. Available from: 2024 Annual Report Letter and 10-K. [Last accessed: November 2025].

 

ABOUT SANDOZ

Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in affordable medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion. 

CONTACTS

Global Media Relations contacts

Investor Relations contacts

Global.MediaRelations@sandoz.com

Investor.Relations@sandoz.com

Alexis Kalomparis
+41 792 790285

Craig Marks
+44 7818 942 383

Chris Lewis
+49 174 244 9501

Tamara Hackl
+41 79 790 5217

Gregor Rodehueser
+49 170 574 3200

Silvia Siegfried
+41 79 795 9061

Viromed Medical AG and HELLMUT RUCK GmbH have concluded an exclusive distribution agreement for plasma devices

Posted on by

Viromed Medical AG / Key word(s): Alliance

Viromed Medical AG and HELLMUT RUCK GmbH have concluded an exclusive distribution agreement for plasma devices

28-Nov-2025 / 17:28 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.

Viromed Medical AG and HELLMUT RUCK GmbH have concluded an exclusive distribution agreement for plasma devices

Rellingen, November 28, 2025 – Viromed Medical AG, a specialist in medical technologies, and HELLMUT RUCK GmbH, a leading provider of podiatry, foot care, and cosmetic solutions, announce the conclusion of an exclusive partnership for Europe, including Switzerland. As part of this cooperation, RUCK will exclusively distribute innovative plasma devices as an OEM product. The collaboration combines the technological expertise of Viromed with the strong market position and sales experience of RUCK. The aim is to provide professional users in podiatry, foot care, cosmetics, and medicine with a forward-looking solution for hygienic and skin-friendly treatments.

 

Notifying person:
Uwe Perbandt, CEO Viromed Medical AG

Contact Viromed:
E-Mail: kontakt@viromed-medical.de

End of Inside Information

28-Nov-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Language: English
Company: Viromed Medical AG
Hauptstraße 105
25462 Rellingen
Germany
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A3MQR65
WKN: A3MQR6
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Tradegate Exchange
EQS News ID: 2237640

 
End of Announcement EQS News Service

2237640  28-Nov-2025 CET/CEST

Xlife Sciences AG Provides Update on VERAXA Biotech AG’s NASDAQ Listing Process Following U.S. Government Shutdown

Posted on by

Following a 43-day U.S. government shutdown, during which the SEC was also affected, the SEC has now responded to VERAXA’s Form F-4 filing submitted at the end of October. The SEC was unable to respond to VERAXA’s Form F-4 during this time. Subsequently, the SEC responded and VERAXA has filed an amendment to the Form F-4 on November 28, marking another important step forward in the planned business combination with Voyager Acquisition Corp. and VERAXA’s intended listing on NASDAQ.

The date of VERAXA’s extraordinary general meeting (EGM), which will address the required shareholder approvals of VERAXA for the business combination, is expected to be scheduled in December 2025. Based on the current timeline and assuming customary regulatory progression, Xlife Sciences expects VERAXA Biotech AG to complete its NASDAQ listing in the first quarter of 2026.

Oliver R. Baumann, CEO of Xlife Sciences AG, commented: «We are pleased to see the SEC process advancing swiftly despite the prolonged shutdown. We remain confident in the transaction timeline and in VERAXA’s trajectory toward becoming a NASDAQ-listed leader in next-generation oncology therapeutics.»

Further details, including an investor presentation and documentation related to the proposed transaction, are available via the SEC’s EDGAR system at www.sec.gov.

 

Financial calendar

Annual Report 2025 28 April 2026
Annual Shareholders Meeting 2026 26 June 2026
Half-Year Report 2026 24 September 2026

Asklepios Group: Solid third quarter of 2025 – successful placement of Social Schuldschein loan strengthens financing basis

Posted on by

Asklepios Kliniken

/ Key word(s): Quarterly / Interim Statement

Asklepios Group: Solid third quarter of 2025 – successful placement of Social Schuldschein loan strengthens financing basis

27.11.2025 / 10:00 CET/CEST

The issuer is solely responsible for the content of this announcement.

Asklepios Group: Solid third quarter of 2025 –  successful placement of Social Schuldschein loan strengthens financing basis
 

  • Patient numbers up 6.3% to reach 2.9 million
  • Consolidated revenues of EUR 4,770.1 million
  • Successful placement of new Social Schuldschein loan for EUR 600.0 million

 

In the first nine months of 2025, the Asklepios Group put in an overall solid operating performance. Despite healthcare policy challenges and a difficult economic environment, the number of patients was once again increased and consolidated profit was improved. Parallel to that, the Group has also given a significant boost to its sustainable financing.

 

From January to September 2025, the Group’s healthcare facilities treated a total of 2,915,971 patients (9M 2024: 2,742,439) – an increase of roughly 6.3% over the previous year. While moderate growth in patient numbers was observed in the inpatient area, the overall trend was mainly driven by growth in the outpatient area.

 

Consolidated revenue totalled EUR 4,770.1 million (9M 2024: EUR 4,350.8 million) in the first nine months, which is an increase of 9.6%. Consolidated net income after tax (EAT) for the period increased to EUR 114.5 million (9M 2024: EUR 88.2 million). Total investments over the reporting period were EUR 302.8 million (9M 2024: EUR 232.4 million).

 

On 29 October 2025, the Asklepios Group successfully placed a Social Schuldschein loan in the amount of EUR 600.0million. It was issued under the Social Finance Framework for early refinancing of maturities for the years 2025 to 2027 and was subscribed by both existing and international investors. With maturities of 3, 5, 7 and 10 years as well as a 52% share of international investors, the capital base was further diversified.

 

Hafid Rifi, CFO of the Asklepios Group, noted:

“The new Social Schuldschein loan allows us to further develop the strategy of our finance portfolio and to actively manage our maturities. What is especially encouraging is the strong interest shown by international investors, clearly underscoring the trust in our sustainable course.“

 

 

About Asklepios

Asklepios Kliniken is one of the leading operators of private hospitals and healthcare facilities in Germany. The hospital group has an established track record for delivering high-quality medical care to its patients with a clear commitment to medical quality, innovation and social responsibility. Currently, the Asklepios Group has some 160 healthcare facilities throughout Germany. These include acute hospitals of all care levels, university hospitals, specialised clinics, psychiatric and forensic facilities, rehabilitation hospitals, nursing homes and medical care centres. During financial year 2024, over 3.6 million patients were treated at Asklepios’ healthcare facilities. The Group employs more than 70,000 persons.

 

The Quarterly Statement can be accessed as of today at Asklepios – Publikationen.

 

Investor Relations contact:

Sarah Ludwig

Head of Investor Relations

Asklepios Kliniken GmbH & Co. KGaA

Debusweg 3 – 61462 Königstein-Falkenstein

Tel.: +49 6174 9011-72

E-mail: ir@asklepios.com

 

Media contact:

Rune Hoffmann

Head of Corporate Communications & Marketing

Asklepios Kliniken GmbH & Co. KGaA

Rübenkamp 226 – 22307 Hamburg

Tel.: +49 40 1818-82 6630

Fax: +49 40 1818-82 6639

E-mail: presse@asklepios.com

 

 

Visit Asklepios on the Internet, Facebook or YouTube:

www.asklepios.com

www.gesundleben.asklepios.com
www.facebook.com/asklepioskliniken
www.youtube.com/asklepioskliniken

 

 

Sign up for the Asklepios Newsletter:

https://www.asklepios.com/konzern/newsletter-anmeldung/

 

Nursing blog: https://wir-sind-pflege.blog/

 

27.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

2236220  27.11.2025 CET/CEST

Viromed confirms talks with an international MedTech company regarding a cooperation in the field of wound care

Posted on by

Viromed Medical AG / Key word(s): Alliance/Miscellaneous

Viromed confirms talks with an international MedTech company regarding a cooperation in the field of wound care

26-Nov-2025 / 17:02 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.

AD HOC ANNOUNCEMENT

Viromed confirms talks with an international MedTech company regarding a cooperation in the field of wound care

Pinneberg, November 26, 2025 – Viromed Medical AG (“Viromed”; ISIN: DE000A3MQR65), confirms market rumors that the company is in advanced talks with a global MedTech company in the field of wound treatment about signing a cooperation agreement. This mainly involves the use of the cold plasma medical device ViroCAP®/OEM to support wound healing.

Viromed will inform shareholders of further developments in an appropriate manner and in accordance with the legal obligations.

Notifying person:
Uwe Perbandt, CEO Viromed Medical AG

Contact Viromed:
E-Mail: kontakt@viromed-medical.de

End of Inside Information

26-Nov-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

Language: English
Company: Viromed Medical AG
Hauptstraße 105
25462 Rellingen
Germany
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A3MQR65
WKN: A3MQR6
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Hamburg, Tradegate Exchange
EQS News ID: 2236382

 
End of Announcement EQS News Service

2236382  26-Nov-2025 CET/CEST

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

Posted on by

Issuer: Immunic AG

/ Key word(s): Conference

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

26.11.2025 / 12:30 CET/CEST

The issuer is solely responsible for the content of this announcement.

Immunic to Participate in the 8th Annual
Evercore ISI Healthcare Conference in December
 

NEW YORK, November 26, 2025 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025 at 9:35 am ET at the 8th Annual Evercore ISI Healthcare Conference, taking place December 2-4, 2025 in Coral Gables, FL.

A webcast will be available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations.

Dr. Vitt and Jason Tardio, President and Chief Operating Officer of Immunic, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Evercore ISI representative or Jessica Breu at: jessica.breu@imux.com. 

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management’s and employee’s participation in investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com

US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com

Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

CureVac Announces Voting Results of Extraordinary General Meeting

Posted on by

Issuer: CureVac

/ Key word(s): AGM/EGM

CureVac Announces Voting Results of Extraordinary General Meeting

26.11.2025 / 00:46 CET/CEST

The issuer is solely responsible for the content of this announcement.

 

CureVac Announces Voting Results of Extraordinary General Meeting

 

TÜBINGEN, Germany / BOSTON, USA – November 25, 2025 – CureVac N.V. (Nasdaq: CVAC)(CureVac or the Company), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of its Extraordinary General Meeting (EGM).

CureVac’s shareholders approved all proposals relating to BioNTech SE’s public exchange offer for all outstanding shares in CureVac (Offer) at the EGM with an approval rate of over 99.16% of the votes cast.

The Offer is set to expire at 9:00 am Eastern Time on December 3, 2025, with CureVac’s shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2025, due to operational deadlines.

Voting results – Overview

A table containing tabulations of the votes cast is set forth below:

Agenda Item 3 Consummation of post-offer reorganization
Agenda Item 3.a. Conditional resolution to enter into a legal merger (juridische fusie) of the Company (as disappearing company) with and into CureVac Merger B.V. (as acquiring company surviving such merger) (New Topco), with New Topco issuing class A shares in its capital to the Company’s shareholders (other than BioNTech SE (Buyer)) and class B shares in its capital to Buyer, in accordance with Sections 2:309 et seq. of the Dutch Civil Code (the Legal Downstream Merger) – accepted
158,803,292 Number of shares for which valid votes were cast (= 70.52% of the registered share capital)
158,646,068 Yes votes 99.95% of the valid votes cast
84,255 No votes 0.05% of the valid votes cast
Agenda Item 3.b. Conditional resolution to approve, to the extent required under applicable law and the Company’s articles of association and bylaws (reglementen), (i) the Legal Downstream Merger, (ii) the subsequent sale and transfer of all outstanding shares in the capital of CureVac SE by New Topco to Buyer and (iii) the subsequent cancellation of all outstanding class A shares in the capital of New Topco – accepted
158,803,292 Number of shares for which valid votes were cast (= 70.52% of the registered share capital)
158,639,956 Yes votes 99.94% of the valid votes cast
89,164 No votes 0.06% of the valid votes cast
Agenda Item 4 Conditional release from liability
Agenda Item 4.a. Conditional release of managing directors from liability for the exercise of their duties – accepted
158,803,292 Number of shares for which valid votes were cast (= 70.52% of the registered share capital)
157,535,455 Yes votes 99.27% of the valid votes cast
1,165,859 No votes 0.73% of the valid votes cast
Agenda Item 4.b. Conditional release of supervisory directors from liability for the exercise of their duties – accepted
158,803,292 Number of shares for which valid votes were cast (= 70.52% of the registered share capital)
157,485,433 Yes votes 99.23% of the valid votes cast
1,219,313 No votes 0.77% of the valid votes cast
Agenda Item 5 Conditional appointment of Ramón Zapata Gomez as managing director of the Company – accepted
158,803,292 Number of shares for which valid votes were cast (= 70.52% of the registered share capital)
157,414,993 Yes votes 99.89% of the valid votes cast
171,497 No votes 0.11% of the valid votes cast
Agenda Item 6 Conditional appointment of supervisory directors
Agenda Item 6.a. Conditional appointment of Sierk Poetting as supervisory director of the Company – accepted
158,803,292 Number of shares for which valid votes were cast (= 70.52% of the registered share capital)
156,296,489 Yes votes 99.18% of the valid votes cast
1,289,511 No votes 0.82% of the valid votes cast
Agenda Item 6.b. Conditional appointment of James Ryan as supervisory director of the Company – accepted
158,803,292 Number of shares for which valid votes were cast (= 70.52% of the registered share capital)
156,260,667 Yes votes 99.16% of the valid votes cast
1,327,264 No votes 0.84% of the valid votes cast
Agenda Item 6.c. Conditional appointment of Annemarie Hanekamp as supervisory director of the Company – accepted
158,803,292 Number of shares for which valid votes were cast (= 70.52% of the registered share capital)
156,257,812 Yes votes 99.16% of the valid votes cast
1,327,765 No votes 0.84% of the valid votes cast

 

About CureVac

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized precision immunotherapy candidates to treat cancer. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.

CureVac Media and Investor Relations Contact

CureVac, Tübingen, Germany

Corporate Communications

communications@curevac.com

Forward-Looking Statements of CureVac

This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the “company”) regarding future events or future results, in contrast with statements that reflect historical facts. Examples include the settlement of all pending patent disputes in the United States between the company, Pfizer, and BioNTech relating to mRNA-based COVID-19 vaccines, the Company’s expectations regarding the outcome of pending litigation in other global jurisdictions, the expected completion of the public exchange offer between BioNTech and the Company, the discussion of the potential efficacy of the company’s vaccine and treatment candidates and the company’s strategies, financing plans, cash runway expectations, the timing and impact of restructuring, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including risks related to the proposed acquisition by BioNTech, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, ability to implement our pipeline strategy, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company’s industry, the effects of the COVID-19 pandemic on the company’s business and results of operations, ability to manage growth, ability to implement, maintain and improve effective internal controls, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings, the impact of adverse settlements or other judicial outcomes and other important factors discussed under the caption “Risk Factors” in the company’s annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 11, 2025, as such factors may be updated form time to time in its other filings with the SEC. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

For further information, please reference the company’s reports and documents filed with the SEC. You may get these documents by visiting EDGAR on the SEC website at www.sec.gov. 

Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

Language: English
Company: CureVac
Friedrich-Miescher-Str. 15
72076 Tübingen
Germany
EQS News ID: 2235868

 
End of News EQS News Service

Straumann Group outlines its mid-term growth strategy to accelerate market shares, strengthen profitability and increase cash generation

Posted on by
  • Strong delivery since 2021: strong 16.2% CAGR organic revenue growth and 32.4% core EBIT margin at constant FX 2021 confirms sustained market outperformance; 9% revenue growth CAGR and EBIT margin at 26% as reported.
  • Well defined playbook for growth: leveraging the powerful combination of leading innovations and advanced digital workflows to make treatments more predictable, faster and more efficient, delivering superior outcomes for customers and patients.
  • The Straumann ecosystem, orchestrated by the AXS platform: a cloud-based platform that seamlessly connects all Straumann solutions and unlocks growth across key business segments. It delivers key services for clinicians and dental laboratories, while supporting the scaling efforts of dental service organizations.
  • Expanding market share across all businesses and customer segments: continued share gains in implantology through a multi-brand strategy, a repositioning of orthodontics for scale and substantial prosthetic growth potential enabled by new and differentiated advanced dental digital technologies.
  • High-performance culture as a strategic asset: engagement score of 82 (top decile globally) supported by strong leadership, talent development and organizational excellence.
  • Translating growth into cash: efficiency programs across the entire organization as well as Capex and working capital management initiatives drive rising profitability and higher free cash flow conversion through 2030.
  • Financial ambition 2030: revenue growth at around 10% CAGR and average profitability increase by 40 to 50 bps core EBIT margin p.a. for 2026-2030 at constant FX.

 

 

Basel, 25 November 2025: At its Capital Markets Day today, Straumann Group presented its next strategic phase towards 2030. Building on the strong foundation and track record laid since 2021, the company has significantly advanced its digital ecosystem leveraging a strong innovation pipeline. As dentistry becomes increasingly digital, Straumann Group is addressing a critical customer need: predictable, efficient and seamless treatment workflows that reduce complexity, save time and improve outcomes for clinicians and patients. With its expanding digital ecosystem and leading innovation track record, supported by a high-performance culture, Straumann Group aims to continue its growth trajectory, strengthen profitability and unlock higher cash generation.

 

 

Guillaume Daniellot, Chief Executive Officer, said:

“Over the past years, we have not only delivered on our ambition but also built something truly distinctive: a growth platform that connects advanced innovations with seamless, data-driven workflows through our Straumann AXS digital platform and the ecosystem around it. We are transforming Straumann Group from a product- to a service-led organization, creating an integrated experience that makes dentistry more predictable, more efficient and more rewarding for professionals and patients. In addition to leading product innovation, this ecosystem is the foundation for our next strategic phase. Thanks to the passion and entrepreneurial mindset of our people, we are ready to unlock the next wave of growth and go beyond in shaping the future of dentistry.”

 

Straumann AXS – A unique platform and ecosystem to unlock growth

Over the years, Straumann Group has significantly invested into its digital ecosystem and innovation pipeline, strengthening its leadership across implants, and posting strong progress in orthodontics and prosthetics. At the center of this ecosystem is Straumann AXS, the Group’s digital platform, which is the backbone that connects customers through seamless, data-driven treatment workflows and supports an integrated clinical experience. Straumann AXS, an open cloud-based platform, is the central hub of the ecosystem, bringing customers into a single, secure and compliant data-driven environment and ensuring a cohesive clinical journey end to end. Every single treatment starts with a scan. The SIRIOS intraoral scanners provide direct access to the Straumann AXS platform and guides clinicians through diagnosis, planning and treatment. By linking hardware, software and services into one connected environment, Straumann AXS creates a scalable platform that enhances clinical efficiency, improves customer experience and opens adjacent growth opportunities within and beyond the Straumann Group’s portfolio.

 

Implantology – Expanding growth leadership in innovation and multi-brand strategy

The implantology business remains the cornerstone of Straumann Group’s performance, with the company holding around 35% global market share and significant untapped potential in a market with roughly 220 million potential patients who need and can afford an implant treatment, with only 16 million being treated per year. In the premium segment, Straumann iEXCEL, Straumann Group’s high-performance implant system for unique clinical capabilities and flexibility, has already surpassed one million implants sold and represent 20% of Straumann premium implant business. It reflects the strong clinician adoption and the clinical strength of the Group’s innovation premium pipeline. In the value segment, our challenger brands are accelerating growth by expanding access to quality implant dentistry in underpenetrated markets via geographical expansion. The multi-brand strategy also enables the Group to serve different clinical preferences of diverse customer groups. Digital tools, education programs and workflow solutions support clinicians across these brands, accelerate our implant businesses growth and help expand share of business. Digital tools, education programs and workflow solutions support clinicians across these brands, accelerate growth in our implant businesses, and help expand our share of business. 

 

 

Orthodontics – Transforming ClearCorrect to become a global leader

Orthodontics is one of the most underpenetrated segments in dentistry, representing a CHF 4.7 billion global market with an expected average growth rate of around 10%. With ClearCorrect, Straumann Group has built a very competitive value proposition, supported by a digital platform that integrates AI-driven treatment planning, manufacturing at scale and remote patient monitoring. The partnership with Smartee provides regional manufacturing agility, new technologies and significantly improves cost efficiency, while the partnership with DentalMonitoring enhances clinical precision and patient compliance through AI-based remote care. This combination of clinical excellence, digital intelligence and scale positions ClearCorrect well in its ambition to become the preferred partner for general practitioners in orthodontics.

 

Prosthetics – Disrupting the digital chairside workflow

Prosthetics is a CHF 6 billion global market that is still largely manual and fragmented, offering significant potential for digital adoption. Straumann Group is an innovator in this segment by integrating prosthetic workflows into its digital ecosystem. Intraoral scanners such as SIRIOS X3 serve as the entry point into the Straumann AXS platform, enabling seamless diagnosis, planning and design. Together with the MIDAS 3D printing technology, SIRIOS X3 enables a unique, fully integrated chairside workflow that connects scanning, design and production in one continuous process. Digital solutions like UNIQ accelerate the design and fabrication of restorations, reducing complexity and improving resource management for labs. By combining hardware, software and consumables into one connected system, Straumann Group unlocks adjacent growth opportunities and strengthens its leadership in digital dentistry.

 

People – High-performance culture driving performance

In an environment that is changing faster than ever, Straumann Group’s culture remains one of its strongest competitive advantages. With an employee engagement score of 82, the Group’s player-learner mindset fosters ownership, adaptability and a continuous drive to improve. To stay ahead, Straumann Group is building the capabilities needed for the future, including digital fluency, cross-functional collaboration and consultative customer engagement. Leadership and talent development programs strengthen the pipeline and ensure that teams can navigate complexity and seize new opportunities. This combination of culture, skills and leadership readiness supports the Group’s ability to grow, innovate and remain resilient in a rapidly evolving industry.

 

Finance – Translating growth to profitability to cash to invest in future growth

Straumann Group is entering into its next strategic phase with a strong balance sheet and clear operational levers to turn growth into cash. The company aims to unlock growth through its playbook of innovation and digitalization, whilst actively managing headwinds on gross profit driven by portfolio, geographic and customer mix. Mitigating levers include the expansion of the implant manufacturing footprint in China – which also enhances natural currency hedging – efficiency gains from ongoing production improvements, strengthened orthodontic partnerships to support profitability, and continued operational excellence. Improved supply chain processes, procurement initiatives and shared services further reduce complexity and operating costs, supported by lower capex requirements and more focused working-capital management.

Together, these measures will support EBIT growth and increase Free Cash Flow conversion by 2030, ensuring the Group’s ability to reinvest into innovation, growth and shareholder returns.

 

Financial ambition for 2030

With its next strategic phase, Straumann Group is planning to deliver revenue growth at around 10% CAGR and average profitability increase by 40 to 50 bps core EBIT margin p.a. for 2026–2030 at constant FX.

***

About Straumann Group

The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials and digital solutions for use in tooth correction, replacement and restoration or to prevent tooth loss.

 

Headquartered in Basel, Switzerland, the Group currently employs close to 12 000 people worldwide. Its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.

 

 

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland   

  Phone: +41 (0)61 965 11 11

Homepage: www.straumann-group.com

 

Contacts:

Corporate Communication

Silvia Dobry: +41 (0)61 965 15 62

Marc Kaiser: +41 (0)61 965 16 80

E-mail: corporate.communication@straumann.com

 

Investor Relations

Marcel Kellerhals: +41 (0)61 965 17 51

Derya Güzel: +41 (0)61 965 18 76

E-mail: investor.relations@straumann.com

 

CAPITAL MARKETS DAY 2025 VIDEO WEBCAST

Straumann Group will present its Capital Markets Day 2025 to representatives of the financial community and media in a live video webcast today at 09.00 a.m. CET. The webcast can be accessed via www.straumann-group.com/webcast. A replay of the webcast will be available after the event.

 

If you intend to ask a question during the Q&A session, we kindly ask you to pre-register for the conference call through this link. We also recommend that you download the presentation file in advance using the direct link in this media release before joining the conference call.

 

 

Presentation

The Capital Markets Day 2025 presentation slides are attached to this release and available on the Media and Investors pages at www.straumann-group.com.

 

 

Disclaimer

This press release contains forward-looking statements that reflect the current views, beliefs and expectations of management at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann’s control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events, or otherwise. This release constitutes neither an offer to sell nor a solicitation to buy any securities.

 

###